News of Note—Pfizer, Meridian Medical Technologies, EpiPen, saline shortage

Newspapers

> Pfizer, which previously received a warning letter for the Meridian Medical Technologies plant that makes EpiPen injectors for Mylan, has reported to Health Canada that manufacturing problems have led to a shortage of the 0.3 mg format of the pen which it expects to have resolved by March 2, 2018. Release

> The FDA says that the shortage of saline has now led to a shortage of empty IV bags which healthcare providers have been using for compounded versions of the solution. Release

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

> Wuhan Chinese Moxibustion Technology Dev. Co., a maker of an updated version of a traditional Chinese medicine, has received an FDA warning letter for GMP failures at its plant in Wuhan, Hubei, China. Letter

Suggested Articles

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Dr. Reddy’s Laboratories has shut 'key' plants worldwide and all data center services as a preventive measure after detecting a data breach.